###begin article-title 0
###xml 46 53 <span type="species:ncbi:9606">Patient</span>
###xml 92 97 <span type="species:ncbi:9606">Human</span>
A Ligand Peptide Motif Selected from a Cancer Patient Is a Receptor-Interacting Site within Human Interleukin-11
###end article-title 0
###begin p 1
Conceived and designed the experiments: MCV AJZ RJG FCLA JL WA RP. Performed the experiments: MCV AJZ RJG RR LGR CDA JL. Analyzed the data: MCV AJZ RJG JS RR LGR CDA APV FCLA MGK WA RP. Contributed reagents/materials/analysis tools: JS FCLA. Wrote the paper: MCV AJZ RJG FCLA WA RP.
###end p 1
###begin p 2
###xml 619 620 615 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 628 629 624 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 159 166 <span type="species:ncbi:9606">patient</span>
###xml 857 862 <span type="species:ncbi:9606">human</span>
###xml 926 931 <span type="species:ncbi:9606">human</span>
Interleukin-11 (IL-11) is a pleiotropic cytokine approved by the FDA against chemotherapy-induced thrombocytopenia. From a combinatorial selection in a cancer patient, we isolated an IL-11-like peptide mapping to domain I of the IL-11 (sequence CGRRAGGSC). Although this motif has ligand attributes, it is not within the previously characterized interacting sites. Here we design and validate in-tandem binding assays, site-directed mutagenesis and NMR spectroscopy to show (i) the peptide mimics a receptor-binding site within IL-11, (ii) the binding of CGRRAGGSC to the IL-11Ralpha is functionally relevant, (iii) Arg4 and Ser8 are the key residues mediating the interaction, and (iv) the IL-11-like motif induces cell proliferation through STAT3 activation. These structural and functional results uncover an as yet unrecognized receptor-binding site in human IL-11. Given that IL-11Ralpha has been proposed as a target in human cancer, our results provide clues for the rational design of targeted drugs.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Hajitou1">[10]</xref>
###xml 352 355 352 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 500 503 500 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 505 508 505 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 560 564 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Kang1">[11]</xref>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Campbell1">[12]</xref>
###xml 266 273 <span type="species:ncbi:9606">patient</span>
Phage display enables identification of tissue-specific or angiogenesis-related molecular signatures on blood vessels and thereby allows ligand-directed delivery [1]-[10]. Previously we showed, through direct screening of a combinatorial peptide library in a cancer patient, that the selective homing peptides localized non-randomly to specific organs [1]; we also identified a cyclic peptide (sequence CGRRAGGSC) targeting prostate vasculature and prostate cancer as an interleukin-11 (IL-11) mimic [1], [2]. In a different line of investigation, Kang et al. [11] proposed a central role for the IL-11 pathway in the genetic progression of malignant tumors metastatic to bone. Activation of members of the signal transduction and activator of transcription (STAT) family, in particular STAT3, was revealed downstream as a consequence of the binding of IL-11 to its corresponding receptor [12].
###end p 4
###begin p 5
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Du1">[13]</xref>
###xml 281 285 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-httpwww.fda.govcderbiologicsproductsopregen112597.htm.1">[14]</xref>
###xml 536 540 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Bravo1">[15]</xref>
###xml 542 546 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Heinrich1">[16]</xref>
###xml 768 772 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Tacken1">[17]</xref>
###xml 773 777 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Barton1">[21]</xref>
###xml 1130 1134 1124 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Dahmen1">[22]</xref>
###xml 1135 1139 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Schleinkofer1">[24]</xref>
###xml 1394 1398 1384 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Boulanger1">[25]</xref>
###xml 1399 1403 1389 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Hermanns1">[27]</xref>
###xml 1623 1627 1613 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Schroers1">[28]</xref>
###xml 1778 1782 1768 1772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Schroers1">[28]</xref>
###xml 1784 1788 1774 1778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Grotzinger1">[29]</xref>
###xml 2423 2427 2397 2401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Campbell1">[12]</xref>
###xml 2429 2433 2403 2407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Du1">[13]</xref>
###xml 2435 2439 2409 2413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Tacken1">[17]</xref>
Although IL-11 was initially characterized as a cytokine with thrombopoietic activity, it was later found to have pleiotropic effects in multiple tissues [13]. Recombinant IL-11 is an FDA-approved drug (oprelvekin; Neumega(R)) used against chemotherapy-induced thrombocytopenia () [14]. Along with more than 10 other four-helix bundle cytokines, including interleukin-6 (IL-6), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin-M (OSM), and cardiotrophin-1 (CT-1), IL-11 belongs to the gp130 or IL-6-type [15], [16]. These cytokines elicit responses by the assembly of oligomeric signaling complexes that contain the transmembrane receptor gp130. The structure of IL-11 has been the subject of molecular modeling and mutagenesis studies [17]-[21]. Research has revealed that IL-11 contains three known receptor-binding sites (I, II and III). Site I of IL-11 binds to the cytokine-receptor homology region (CHR) in domains 2 and 3 (D2-D3) of IL-11Ralpha, whereas sites II and III interact with two separate areas of the gp130 homodimer: the CHR (D2-D3, site II) and the Ig-like domain (D1, site III) [22]-[24]. However, no direct structural analysis is available for either IL-11 or the signaling complex. In fact, while the X-ray structure of the IL-6 receptor complex as a hexameric IL-6/IL-6Ralpha/gp130 ternary complex has been introduced as a model for IL-11 [25]-[27], the accuracy of this extrapolation has actually been challenged because IL-11 and IL-6 share no significant similarity in primary structure and interact with different receptors presumably through different mechanisms [28]. A ligand-induced transition from an active tetrameric complex (including a gp130 dimer) to an inactive hexameric complex has been proposed for IL-11 [28], [29]. Responsiveness to IL-11 is restricted to cells expressing IL-11Ralpha in addition to gp130. In analogy to the IL-6 receptor alpha (IL-6Ralpha) and IL-6, it has been postulated that IL-11Ralpha "presents" IL-11 to gp130, which is recruited as a homodimer and leads to the generation of a so-called high affinity IL-11 receptor complex. This active complex is the initiating step in the activation of Janus kinase (JAK)/Tyk tyrosine kinases, which in turn phosphorylate tyrosine residues in the cytoplasmic region of gp130; these subsequently serve as docking sites for members of the STAT family of transcription factors, e.g., STAT3 [12], [13], [17].
###end p 5
###begin p 6
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 97 100 97 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 228 232 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Tacken1">[17]</xref>
###xml 233 237 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Schroers1">[28]</xref>
###xml 610 615 <span type="species:ncbi:9606">human</span>
Although the in vivo-selected homing motif CGRRAGGSC had certain ligand-specific attributes [1], [2], the corresponding location within the native cytokine is not in an established interacting site between IL-11 and IL-11Ralpha [17]-[28]. We hypothesized and subsequently confirmed that this peptide motif functions as a new binding site within IL-11. Tandem site-directed mutagenesis, binding assays, nuclear magnetic resonance (NMR) spectroscopy, and signal transduction analysis strongly support the conclusion that this peptide sequence is indeed a previously unrecognized receptor-interacting site within human IL-11.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
Selected sequence-binding to the IL-11 receptor complex is specific and does not include gp130
###end title 8
###begin p 9
###xml 222 225 215 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 227 230 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 354 358 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Bravo1">[15]</xref>
###xml 417 420 406 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 422 425 411 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 690 699 671 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g001">Figure 1A</xref>
###xml 840 849 817 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g001">Figure 1A</xref>
###xml 1369 1378 1338 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g001">Figure 1B</xref>
###xml 611 617 <span type="species:ncbi:9913">Bovine</span>
###xml 821 826 <span type="species:ncbi:9606">human</span>
We have previously established that phage displaying the motif CGRRAGGSC specifically interacts with IL-11Ralpha; this interaction was inhibited by recombinant IL-11 in a concentration-dependent manner but not by IL-1beta [1], [2]. Because the functional IL-11 receptor complex appears to be a multi-heterodimer composed of IL-11, IL-11Ralpha, and gp130 [15], we first evaluated whether the selected IL-11-like motif [1], [2] would bind to IL-11Ralpha, to gp130, or to both. For this purpose, we coated plates with the following protein: IL-11Ralpha, gp130, or the leptin receptor (an unrelated gp130 partner). Bovine serum albumin (BSA) served as a negative control for the binding assay (Figure 1A). CGRRAGGSC-phage did not bind above background levels to immobilized gp130, in comparison to its significant binding to human IL-11Ralpha (Figure 1A), data indicating no phage binding to gp130 alone. Moreover, CGRRAGGSC-phage binding to the leptin receptor or to BSA was undistinguishable from that of untargeted control phage. These results establish that the CGRRAGGSC peptide only binds to IL-11Ralpha in the receptor complex when individual subunits are analyzed. We next showed that CGRRAGGSC-phage binding to IL-11Ralpha is mediated by the IL-11-like motif, because synthetic CGRRAGGSC inhibited binding of the cognate phage in a concentration-dependent manner (Figure 1B).
###end p 9
###begin title 10
Binding of IL-11-like peptides to IL-11Ralpha.
###end title 10
###begin p 11
(A) CGRRAGGSC-phage binding to the individual receptor components of the IL-11 receptor complex: IL-11Ralpha and gp130. Leptin receptor and BSA served as negative controls for binding. (B) Concentration-dependent binding inhibition of CGRRAGGSC-phage to IL-11Ralpha by the cognate synthetic peptide. Bars represent mean+/-standard error of the mean (SEM).
###end p 11
###begin title 12
NMR spectroscopy of the targeted peptide-receptor interaction
###end title 12
###begin p 13
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Giordano2">[30]</xref>
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Valente1">[31]</xref>
###xml 822 826 810 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Giordano2">[30]</xref>
###xml 827 831 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Pires1">[32]</xref>
###xml 970 974 954 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Giordano2">[30]</xref>
###xml 976 980 960 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Pires1">[32]</xref>
###xml 1107 1108 1091 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1161 1171 1139 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003452.s001">Figure S1A</xref>
###xml 1378 1388 1350 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003452.s001">Figure S1A</xref>
###xml 1533 1537 1505 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Giordano2">[30]</xref>
###xml 1727 1728 1699 1700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1752 1760 1724 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003452.s002">Table S1</xref>
###xml 1765 1767 1737 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003452.s003">S2</xref>
NMR is a particularly suitable methodology to study medium-to-low affinity binding [30], [31], which is often the case for the interaction between peptide ligands identified by phage display (such as CGRRAGGSC peptide and IL-11Ralpha). By measuring subtle changes in the NMR parameters of the ligand (such as chemical shifts and relaxation times) one can probe binding events that occur at the microM to mM concentration range due to the fast exchange between the bound conformation and free form of the ligand. Once the fast exchange regiment is reached an excess of ligand (mM) over the receptor (microM) can be employed for the measurements. Fast exchange condition is frequently present in binding studies involving peptides selected from phage display libraries because of their inherent medium to low affinity range [30]-[32]. Thus, to characterize the structural basis of the interaction between the peptide CGRRAGGSC and IL-11Ralpha, we applied NMR-spectroscopy [30], [32]. We began by analyzing the structural behavior of the free synthetic peptide CGRRAGGSC by proton NMR. The one-dimensional (1D-1H-NMR) spectrum displayed broad lines at 25degreesC (Figure S1A) indicating the presence of conformational exchange among multiple CGRRAGGSC conformers. Although the resonance line became more defined at 5degreesC, conformational exchange persisted at low temperatures (Figure S1A); indeed, the occurrence of multiple conformers is not uncommon in this setting and has not precluded the study of ligand receptor interactions [30]. In the case of CGRRAGGSC peptide almost all the resonances in the spectra were unambiguously assigned to the individual residues of the peptide based on two-dimensional proton spectra (2D-1H-NMR) TOCSY and NOESY (Table S1 and S2).
###end p 13
###begin p 14
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Giordano2">[30]</xref>
###xml 467 476 443 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2A</xref>
###xml 571 572 547 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 727 739 699 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figures 2A&#8211;C</xref>
###xml 1076 1085 1044 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2A</xref>
Having characterized the structural behavior of the CGRRAGGSC peptide in solution and assigned its resonances in the NMR spectra, we next set up binding assays [30] to gain insight into the basis for receptor binding to the ligand peptide. The spectrum of free CGRRAGGSC was compared to those of CGRRAGGSC in the presence of IL-11Ralpha (under a molar excess of peptide of approximately16-, 33- and 66-fold), and changes in chemical shift (Deltadelta) were analyzed (Figure 2A). Although the precise mapping of the residues in CGRRAGGSC could not be achieved from the 1D-1H-NMR spectra due to receptor peak overlap, the interaction between CGRRAGGSC and IL-11Ralpha resulted in chemical shift alterations and new spin systems (Figures 2A-C). Such changes are indicative of binding and are suggestive that multiple residues contribute to the interaction. Moreover, the binding equilibrium was dependent on peptide concentration and consistent with a fast exchange rate (micros range) due to the resonances of free and bound forms of the peptide were detected as average bands (Figure 2A).
###end p 14
###begin title 15
Structural basis of the interaction between CGRRAGGSC and IL-11Ralpha.
###end title 15
###begin p 16
###xml 97 98 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 559 560 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 850 851 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 878 879 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
(A) Effect of the CGRRAGGSC peptide concentration upon biding to IL-11Ralpha. Amide region of 1D-1H-NMR spectra of increasing molar concentrations of the peptide CGRRAGGSC binding to IL-11Ralpha (6 microM) is shown (blue). CGRRAGGSC peptide alone (400 microM) and the spectrum of IL-11Ralpha alone are also shown (in red and black, respectively). The appearance of arginine side-chain resonances (not seen in the spectrum of the peptide alone) is indicated (*). (B) Chemical shift changes induced on the CGRRAGGSC resonances by binding to IL-11Ralpha. The 2D-1H-NMR TOCSY spectra of CGRRAGGSC (400 microM) either alone (black) or in the presence of 6 microM IL-11Ralpha (red) are shown. Single-headed and double-headed arrows indicate chemical shift changes and the appearance of new spin-systems, respectively. (C) Composition of amide region of 1D-1H-NMR and corresponding 2D-1H-NMR TOCSY spectra of the CGRRAGGSC peptide at 5degreesC (left), at 25degreesC (middle) and at 25degreesC in the presence of IL-11Ralpha (right). The circles with dotted lines and the arrow indicate arginine resonances.
###end p 16
###begin p 17
###xml 163 164 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 281 290 253 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2B</xref>
###xml 295 302 267 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003452-t001">Table 1</xref>
###xml 372 389 344 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figures 2B and 2C</xref>
###xml 402 403 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 660 669 620 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2B</xref>
###xml 674 681 634 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003452-t001">Table 1</xref>
###xml 904 905 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1003 1006 951 954 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1/9</sup>
###xml 1050 1051 990 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1056 1057 996 997 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1062 1063 1002 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1068 1069 1008 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 1078 1079 1018 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 1142 1143 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1158 1167 1098 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2A</xref>
###xml 1229 1232 1169 1172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1/9</sup>
###xml 1237 1240 1177 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/4</sup>
###xml 1249 1250 1189 1190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1252 1283 1192 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2B, double-headed arrows</xref>
###xml 1718 1719 1654 1655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1736 1737 1672 1673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1799 1808 1723 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2C</xref>
###xml 1814 1815 1738 1739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1820 1821 1744 1745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1829 1830 1753 1754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1894 1915 1812 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2C, left panel</xref>
###xml 1955 1978 1867 1890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2C, middle panel</xref>
###xml 2109 2113 2021 2025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Valente1">[31]</xref>
###xml 2115 2119 2027 2031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-CruzeiroSilva1">[33]</xref>
###xml 2120 2124 2032 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-HenzlerWildman2">[35]</xref>
###xml 2195 2196 2103 2104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 2201 2202 2109 2110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 2210 2211 2118 2119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 2261 2283 2163 2185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g002">Figure 2C, right panel</xref>
To calculate the individual chemical shift changes (Deltadelta) induced by IL-11Ralpha upon each of the hydrogen atoms of CGRRAGGSC, we compared the individual 2D-1H-NMR TOCSY spectra obtained in the absence and presence of IL-11Ralpha (molar peptide excess approximately66-fold) (Figure 2B and Table 1). These spectra were also used for the analysis of new spin systems (Figures 2B and 2C). In the 2D-1H-NMR TOCSY the receptor NMR signal was filtered during the 80 ms spin lock, resulting in a cleaner analysis of chemical shift perturbation. We observed that most individual resonances in CGRRAGGSC showed significant Deltadelta upon binding to IL-11Ralpha (Figure 2B and Table 1), a result indicating that nearly all residues within CGRRAGGSC participate in the binding to the receptor in a direct or indirect manner. The most prominent Deltadelta (>10 Hz) involved the alpha-hydrogen atoms of the Gly7 and of the Cys residues (which could not be unambiguously assigned and here is referred to as Cys1/9). However, Deltadelta>5 Hz for residues Cys1, Gly2, Gly6, Ser8, and Cys9 were also noteworthy. The new spin systems observed in the 1D-1H-NMR spectra (Figure 2A) also appeared in the TOCSY spectra, and were assigned to Cys1/9, Arg3/4, and Ala5 (Figure 2B, double-headed arrows). These new spin systems map to the peptide region that undergoes a complex conformational equilibrium in the free state. This result suggests that, upon binding to IL-11Ralpha, the segment Cys-s-s-Cys-Gly-Arg-Arg-Ala in CGRRAGGSC becomes conformationally constrained, resulting in a gain-of-structure and corresponding loss-of-freedom for CGRRAGGSC in the bound state. Consistently, similar results were observed by comparing the 1D-1H-NMR and the 2D-1H-NMR TOCSY spectra of CGRRAGGSC at 5degreesC and 25degreesC (Figure 2C). Arg3, Arg4 and Ala5 resonances could only be detected in the spectra at 5degreesC (Figure 2C, left panel) but not in the spectra at 25degreesC (Figure 2C, middle panel), again indicative that conformational variability plays a role when detecting such spin systems which has been recently reported [31], [33]-[35]. However, upon binding to IL-11Ralpha, resonances corresponding to Arg3, Arg4 and Ala5 were also observed in the spectra at 25degreesC (Figure 2C, right panel).
###end p 17
###begin title 18
Individual chemical shift changes in CGRRAGGSC upon interaction with IL-11Ralpha.
###end title 18
###begin p 19
###xml 56 60 44 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">free</sub>
###xml 66 71 50 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bound</sub>
###xml 185 186 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
Differences in chemical shift change (Deltadelta = deltafree-deltabound) were determined in free CGRRAGGSC (400 microM) and in the presence of IL-11Ralpha (6 microM) calculated from 2D-1H-TOCSY. Bold and italicized numbers represent chemical shift changes greater than 5 Hz. Labile resonances were not detected (N.D.) due to fast solvent exchange or receptor peak overlap.
###end p 19
###begin p 20
###xml 511 512 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 520 521 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
Taken together, our NMR data indicate that conformational variability plays a structural role in CGRRAGGSC peptide interaction with IL-11Ralpha and suggest that: (i) most residues in CGRRAGGSC change their conformation upon binding to IL-11Ralpha, (ii) the Cys-s-s-Cys-Gly-Arg-Arg-Ala domain of the peptide undergoes a receptor-dependent gain-of-structure, (iii) the motif Gly-Gly-Ser-Cys-ss-Cys encompasses a candidate site for direct interaction of the peptide with IL-11Ralpha, and (iv) that the residues Gly7 and Ser8, in agreement with the mutational studies (described below), are also relevant for binding.
###end p 20
###begin title 21
Functional analysis of wild-type and site-directed IL-11 mutants
###end title 21
###begin p 22
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Tacken1">[17]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Barton1">[21]</xref>
###xml 468 473 <span type="species:ncbi:9606">human</span>
In previous work, other investigators have produced recombinant proteins containing point mutations to unveil functional attributes of the native IL-11; notably, point mutations within the site containing the CGRRAGGSC sequence have not been reported [17]-[21]. Thus, to further demonstrate that residues 112-117 represent a protein-interacting site, we first attempted to generate a series of recombinant site-directed alanine-scan mutants of the motif RRAGGS within human IL-11.
###end p 22
###begin p 23
###xml 63 72 63 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g003">Figure 3A</xref>
###xml 424 433 424 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g003">Figure 3B</xref>
###xml 647 650 643 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">113</sup>
###xml 663 666 659 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">115</sup>
###xml 683 686 679 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">117</sup>
###xml 865 868 861 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">112</sup>
###xml 884 887 880 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">116</sup>
###xml 975 984 971 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g003">Figure 3C</xref>
###xml 1112 1115 1104 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">115</sup>
###xml 1123 1126 1115 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">117</sup>
###xml 1356 1365 1344 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g003">Figure 3C</xref>
Whereas DNA sequencing (data not shown) and SDS-PAGE analysis (Figure 3A) showed that the wild-type and mutant IL-11 recombinant proteins were produced with the expected molecular weight, a number of IL-11 mutants presented steric hindrance and misfolding aberrances. Such inherent technical limitation of any mutational study is evident from the lack of epitope accessibility observed in studies with anti-IL11 antibodies (Figure 3B and data not shown). Despite these potential issues, we next used ELISA to assess the attributes of IL-11 point mutants (residues 112-117) for their ability to bind to the IL-11Ralpha. Mutation of the residues Arg113 (R113A), Gly115 (G115A), and Ser117 (S117A) markedly reduced binding of IL-11 to the receptor, relative to the wild-type sequence (86, 71, and 86% binding inhibition, respectively), whereas mutation of residues Arg112 (R112A) and Gly116 (G116A) produced only a moderate effect (43 and 29% binding inhibition, respectively) (Figure 3C). These data indicate that most of the residues within the RRAGGS motif participate in the binding to IL-11Ralpha; however, Gly115 and Ser117 are likely the key residues mediating the ligand-receptor interaction. Thus, consistent with our working hypothesis, the alanine-scan mutants did show reduced, albeit specific, binding to the corresponding receptor, IL-11Ralpha (Figure 3C).
###end p 23
###begin title 24
Binding of wild-type or site-directed mutants of IL-11 to IL-11Ralpha.
###end title 24
###begin p 25
(A) Purified recombinant proteins were analyzed by Coomassie staining. (B) Western blot analyses with polyclonal anti-IL-11 and anti-GST antibodies. (C) Recombinant GST fusion proteins (alanine scan mutants of residues 112-117 of IL-11, wild-type IL-11, GST alone, or rhIL-11) were coated in triplicate overnight and incubated with IL-11Ralpha. Binding was detected with anti-Fc antibody. Bars represent mean+/-standard error of the mean (SEM).
###end p 25
###begin p 26
###xml 23 26 23 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">113</sup>
###xml 616 623 608 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003452-t002">Table 2</xref>
###xml 641 642 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 647 648 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 656 657 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 721 728 713 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003452-t002">Table 2</xref>
###xml 763 764 755 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 772 773 764 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1106 1107 1094 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 1154 1157 1142 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">117</sup>
###xml 1318 1323 <span type="species:ncbi:9606">human</span>
The role of residue Arg113 is somewhat problematic to evaluate from ELISA, because this mutation affected the reactivity of the anti-IL-11 antibodies. To rule out the possibility that the observed reduction in binding of the IL-11 mutants to the IL-11Ralpha was secondary to misfolding of the full-length protein and/or steric hindrance, we devised an alternative ligand-receptor assay based on site-directed mutagenesis of peptide-targeted phage. Single-residue alanine scanning mutagenesis of the CGRRAGGSC phage were produced and binding of each phage to immobilized IL-11Ralpha was tested in a functional assay (Table 2). Mutation of Arg4, Gly7 and Ser8 residues in CGRRAGGSC phage abrogated binding to the receptor (Table 2), whereas mutation of residues Arg3 and Gly6 did not inhibit binding but reduced the CGRRAGGSC-receptor interaction by over 70%. These data are in agreement with the NMR and the IL-11 site-directed mutagenesis studies and indicate that most residues within the RRAGGS motif participate in the interaction with IL-11Ralpha. Moreover, the data identify a central role for the Ser8 residue in CGRRAGGSC (corresponding to the Ser117 of IL-11) in binding to the receptor and indicate that both glycine residues are important for interaction with IL-11Ralpha. In conclusion, residues 112-117 in human IL-11 comprise a structural and functional site for the interaction of the protein with its receptor.
###end p 26
###begin title 27
Phage binding to IL-11Ralpha.
###end title 27
###begin p 28
###xml 48 51 44 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+++</bold>
###xml 58 60 54 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++</bold>
###xml 69 70 65 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</bold>
###xml 78 79 74 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</bold>
Ratio of Binding to IL-11Ralpha/Binding to BSA: +++: >30; ++: 15-30; +: 6-15; -: <6.
###end p 28
###begin p 29
Positive control.
###end p 29
###begin p 30
Scrambled control; Negative control, insertless.
###end p 30
###begin title 31
The synthetic peptide CGRRAGGSC induces cell proliferation
###end title 31
###begin p 32
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Fourcin1">[36]</xref>
###xml 783 804 779 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g004">Figure 4A, left panel</xref>
###xml 912 934 904 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g004">Figure 4A, right panel</xref>
###xml 936 939 928 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 1559 1568 1539 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g004">Figure 4B</xref>
###xml 1757 1766 1729 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g004">Figure 4B</xref>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 248 253 <span type="species:ncbi:9606">human</span>
Having shown that the motif RRAGGS represents a relevant site within human IL-11, we proceeded to determine whether the corresponding synthetic peptide is biologically active. IL-11 induces concentration-dependent proliferation when incubated with human TF-1 leukemia cells ([36]; and data not shown). Thus, we evaluated whether the corresponding synthetic CGRRAGGSC peptide mimics IL-11 in its stimulation of these cells upon binding to the IL-11Ralpha. We first exposed TF-1 cells to the CGRRAGGSC peptide in the presence or absence of either IL-11 or GM-CSF (positive control) under pre-determined conditions in which IL-11 induces optimal cell proliferation. Soluble CGRRAGGSC peptide induced a potent growth-stimulatory effect on TF-1 cells, alone and in the presence of IL-11 (Figure 4A, left panel) or GM-CSF (data not shown), whereas no effect was observed on control (non-IL-11Ralpha-expressing) cells (Figure 4A, right panel) [2]. This peptide-induced proliferative effect was more pronounced for CGRRAGGSC plus IL-11 or CGRRAGGSC alone than for CGRRAGGSC plus GM-CSF (data not shown); an unrelated cyclic control peptide did not show detectable effects by itself or in combination with IL-11. Next, to evaluate whether CGRRAGGSC-induced proliferation is dependent on cell surface IL-11Ralpha, we used the corresponding soluble receptor, sIL-11Ralpha, as a molecular decoy for peptide binding. Cell proliferation induced by CGRRAGGSC was lower in the presence of sIL-11Ralpha (t-test, P<0.005) but not in the presence of a control soluble receptor (Figure 4B). Of note, less inhibition was observed when cells were cultured with CGRRAGGSC, sIL-11Ralpha and IL-11, data indicating that CGRRAGGSC might interact with the complex IL-11-sIL-11Ralpha (Figure 4B). These results show that the synthetic peptide CGRRAGGSC can induce cell proliferation by itself, possibly acting as an IL-11Ralpha-stimulatory ligand.
###end p 32
###begin title 33
Biological effects of the IL-11-like peptide CGRRAGGSC on IL-11-responsive cells.
###end title 33
###begin p 34
###xml 99 104 <span type="species:ncbi:9606">human</span>
(A) Concentration-dependent proliferative response to CGRRAGGSC is shown on IL-11Ralpha-expressing human TF-1 leukemia cells in the absence or presence of IL-11 (left panel). No response is observed on non-IL-11Ralpha-expressing control cells (right panel). (B) Soluble IL-11Ralpha-mediated inhibition of the proliferative effect induced by 150 microM CGRRAGGSC peptide (and by IL-11). * t-test, P<0.005. Bars represent mean+/-standard error of the mean (SEM).
###end p 34
###begin title 35
STAT3 phosphorylation mediates CGRRAGGSC-induced cell proliferation
###end title 35
###begin p 36
###xml 466 469 462 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">705</sup>
###xml 532 540 528 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g005">Figure 5</xref>
###xml 649 658 645 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g005">Figure 5A</xref>
###xml 714 723 710 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g005">Figure 5B</xref>
###xml 868 877 864 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g005">Figure 5A</xref>
IL-11 binding to IL-11Ralpha and glycoprotein 130 (gp130) mediates signal transduction through STAT3 activation; therefore, we next evaluated whether the CGRRAGGSC peptide might stimulate cell proliferation by activation of the same pathway. To that end, we examined ligand-mediated STAT3 activation in serum-starved TF-1 cells incubated in the presence of IL-11, CGRRAGGSC peptide, or an unrelated cyclic control peptide. Despite serum starvation, weak STAT3 (P-Tyr705) baseline activation was detected in unstimulated TF-1 cells (Figure 5). Twenty minutes incubation with either CGRRAGGSC or IL-11 (positive control) led to STAT3 phosphorylation (Figure 5A), which increased in a concentration-dependent manner (Figure 5B). Similar effects were observed for IL-11 in combination with CGRRAGGSC or an unrelated cyclic peptide (but not for the control peptide alone) (Figure 5A). These data uncover a potential molecular mechanism underlying CGRRAGGSC-induced proliferation via activation of the IL-11 receptor complex through STAT3 and indicate that this site within IL-11 is functionally active for binding and signal transduction.
###end p 36
###begin title 37
The IL-11-Like peptide CGRRAGGSC induces STAT3 activation upon binding to IL-11Ralpha in a concentration-dependent manner.
###end title 37
###begin p 38
###xml 146 149 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">705</sup>
###xml 419 422 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">705</sup>
###xml 21 26 <span type="species:ncbi:9606">human</span>
(A) Proliferation of human TF-1 leukemia cells induced by CGRRAGGSC is associated with STAT3 phosphorylation, as assessed with an anti-STAT3-P-Tyr705 antibody. (B) CGRRAGGSC peptide-induced activation of STAT3 is concentration dependent. No effect is observed with a control peptide. To avoid inter-experimental variation, the lysate was divided in two: one-half of the lysate was immunoblotted with an anti-STAT3-P-Tyr705 antibody whereas the other half served to determine the total amount of STAT3 (as a surrogate for protein loading) with a specific anti-STAT3 antibody. Note that the commercial HeLa cell extracts serving as controls display only the proportional, variant-STAT3 band.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 58 61 58 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 63 67 63 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Pentz1">[37]</xref>
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Pentz2">[38]</xref>
###xml 150 153 150 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 237 240 233 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 416 420 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Dahmen1">[22]</xref>
###xml 421 425 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Schleinkofer1">[24]</xref>
###xml 500 508 496 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g006">Figure 6</xref>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 404 409 <span type="species:ncbi:9606">human</span>
Through direct selection of peptide libraries in patients [1], [37], [38], we isolated a ligand peptide mimicking IL-11 from the prostate vasculature [1] and proposed the IL-11Ralpha as a target during the progression of prostate cancer [2]. Here we elected to explore the structural and functional attributes of this putative protein-protein interaction because the currently known binding sites within human IL-11 [22]-[24] do not encompass the selected peptide sequence within the native protein (Figure 6).
###end p 40
###begin title 41
###xml 33 38 <span type="species:ncbi:9606">human</span>
Residues identified within known human IL-11 binding sites.
###end title 41
###begin p 42
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Tacken1">[17]</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Barton1">[21]</xref>
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 255 258 255 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Boulanger2">[47]</xref>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 329 334 <span type="species:ncbi:9606">human</span>
Arrowheads indicate human IL-11 residues predicted (through site-directed mutagenesis) to be ligand-receptor binding sites; solid colors specify residues that are critical for binding [17]-[21]. Residues 112-117 corresponding to the IL-11-like motif [1], [2] described in this work are highlighted in yellow. The basic scheme of human IL-11, as shown here, has been modified from reference [47].
###end p 42
###begin p 43
###xml 277 278 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 285 286 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 441 442 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 614 615 606 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 706 707 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
We used complementary strategies such as site-directed mutagenesis and NMR-based studies to establish that all six residues of the RRAGGS motif are likely required for binding to IL-11Ralpha. Because NMR analysis did not unambiguously reveal which of the arginine residues (Arg3 or Arg4) participates in receptor binding, studies based on targeted phage alanine scanning and IL-11 site-directed mutagenesis were indicated. In both cases, Arg4 turned out to be the key residue. All three methods also suggested that Gly and Ser residues contribute to the level of IL-11Ralpha binding by the ligands. Indeed, the Ser8 mutation abolished the binding of CGRRAGGSC to IL-11Ralpha; the Deltadelta observed in Ser8 induced by binding to IL-11Ralpha corroborated this result.
###end p 43
###begin p 44
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Barton1">[21]</xref>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Somers1">[39]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Barton1">[21]</xref>
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-McDonald1">[40]</xref>
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Panayotatos1">[41]</xref>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Hudson1">[43]</xref>
###xml 497 501 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Tacken1">[17]</xref>
###xml 502 506 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Barton1">[21]</xref>
###xml 526 530 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Somers1">[39]</xref>
###xml 874 878 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Ciapponi1">[44]</xref>
###xml 879 883 875 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Kallen1">[46]</xref>
###xml 1213 1217 1209 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Boulanger2">[47]</xref>
###xml 1521 1525 1513 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-MullerNewen1">[26]</xref>
###xml 1527 1531 1519 1523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Boulanger2">[47]</xref>
###xml 1778 1786 1770 1778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003452-g006">Figure 6</xref>
###xml 2106 2110 2090 2094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Lebeau1">[48]</xref>
We have attempted to generate and interpret molecular models of IL-11 based on high-resolution structural studies available for other gp130-type cytokines, including IL-6 [21], [39] and CNTF [21], [40] and on mutagenesis of IL-6, CNTF and LIF [41]-[43]. In the case of the binding site for IL-11Ralpha or site I, directed mutagenesis of specific residues at the C-terminus of helix D and the AB loop established that these regions participate in receptor binding and cytokine-mediated bioactivity [17]-[21], analogous to IL-6 [39]. Both locations are positioned close to each other in these models and occupy the C-terminus of the four-helix bundle structure, which is situated opposite the BC loop. Similar structural and mutagenesis-based studies on gp130-type cytokines (vIL-6, CNTF and LIF) implicated residues within the BC loop in receptor recognition and bioactivity [44]-[46]. However, such residues were part of site II or site III (for interaction with gp130 or gp130/LIF receptor), and not site I. Notably, the crystal structure of the IL-6 receptor complex hexamer demonstrated no role in IL-6 receptor binding for the BC loop, which is facing the N-terminal region of D2 in the second gp130 molecule [47]. Our data show that CGRRAGGSC is a peptide mimic of IL-11, and as such is capable of recognizing and binding to IL-11Ralpha to activate cell signaling and proliferation. Although it is generally assumed that the model for the cell membrane-bound IL-11 receptor complex would be similar to that for IL-6 [26], [47], certain structural characteristics in the complex subunits may actually diverge significantly. For instance, we noticed the existence of four unreported leucine-zippers within IL-11 (three of them extending from the BC loop through the helix C, Figure 6). They have no clear parallel among most other gp130-type cytokines (only OSM and CT-1 appear to contain one of such regions). Moreover, there are two IL-11Ralpha membrane-bound isoforms that differ by the presence or absence of a cytoplasmic domain, whereas IL-6Ralpha has only one form with a longer cytoplasmic tail [48]. Such isoforms could participate in the formation of a receptor complex unlike those observed in the IL-6Ralpha complex formation. Future detailed X-ray crystallography of the IL-11 receptor complex will further elucidate these fine structural features.
###end p 44
###begin p 45
###xml 744 748 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Wrighton1">[49]</xref>
###xml 960 964 948 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Livnah1">[50]</xref>
###xml 980 984 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Cwirla1">[51]</xref>
###xml 1202 1206 1190 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Livnah2">[52]</xref>
###xml 1208 1212 1196 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Seubert1">[53]</xref>
###xml 1399 1403 1387 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Pillutla1">[54]</xref>
Functionally, the IL-11 mimic peptide CGRRAGGSC showed biological effects mediated by IL-11Ralpha (concentration-dependent stimulation of cell proliferation) both in the presence and in the absence IL-11. Furthermore, CGRRAGGSC-mediated cell proliferation in the presence of sIL-11Ralpha was reduced, and to a greater degree in the presence of native IL-11, but was not affected by an unrelated control receptor. Based on these findings, one might speculate on an interaction between the peptide CGRRAGGSC and the complex IL-11/IL-11Ralpha. Indeed, the soluble peptide CGRRAGGSC was found to induce STAT3 phosphorylation in the same manner as the IL-11 native cytokine. These results have biological precedent in other systems. Wrighton et al. [49] isolated peptides that bind to and activate the erythropoietin receptor (EPOR); crystallographic analysis of the receptor complex revealed a peptide that generated a functional symmetric arrangement of the EPOR [50]. Cwirla et al. [51] selected peptide agonists for the thrombopoietin receptor and proposed an activation mechanism. Recent studies have also shown that orientation and residence time of ligand-receptors must be considered for activation [52], [53]. Moreover, peptides selected for binding to certain receptors bind to several sites on the receptor and activation might occur through conformational changes rather than multimerization [54].
###end p 45
###begin p 46
###xml 412 416 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Schroers1">[28]</xref>
###xml 418 422 414 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Varghese1">[55]</xref>
###xml 424 428 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Schuster1">[56]</xref>
###xml 604 608 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-httpwww.fda.govcderbiologicsproductsopregen112597.htm.1">[14]</xref>
###xml 610 614 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Greiser1">[57]</xref>
###xml 615 619 611 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Skiniotis1">[59]</xref>
From a supra-molecular viewpoint, IL-11 receptor complex formation is in all probability intricate: the ligand cytokine (IL-11) may need to bind first to a presenting receptor subunit (IL-11Ralpha) and subsequently recruit a dimer of signaling subunits (i.e., gp130). Studies of the related IL-6 receptor complex support the contention that preformed inactive dimers of receptor subunits exist in cell membranes [28], [55], [56]. Previous reports determined that gp130-dimerization is not sufficient for receptor activation and that active conformational adjustment is required for a biological response [14], [57]-[59]. Therefore, it is possible that the soluble peptide CGRRAGGSC in complex with IL-11Ralpha might strengthen gp130-dimerization and/or induce a signaling-competent conformation.
###end p 46
###begin p 47
The strength of combining various functional assays (site-directed mutagenesis of native proteins in tandem with ELISA plus peptide-alanine scanning in tandem with targeted phage binding assays) with structural studies (NMR-based spectroscopy of the peptide-receptor interaction) may overcome some of the limitations of mutational studies in the determination of binding sites of ligand-receptor interactions (such as difficult gene/protein expression, and mutant protein misfolding or steric hindrance).
###end p 47
###begin p 48
###xml 87 92 <span type="species:ncbi:9606">human</span>
In summary, we have shown that (i) the RRAGGS sequence (corresponding to a site within human IL-11, residues 112-117) mimics a candidate protein-binding site within IL-11, (ii) the molecular interaction between the peptide CGRRAGGSC and IL-11Ralpha is functional, and (iii) the IL-11-like motif induces proliferation of responsive cells through IL-11Ralpha-mediated STAT3 activation.
###end p 48
###begin title 49
Materials and Methods
###end title 49
###begin title 50
Reagents
###end title 50
###begin p 51
###xml 366 369 362 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">705</sup>
###xml 685 688 677 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 690 693 682 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 267 272 <span type="species:ncbi:9606">human</span>
The following antibodies were obtained commercially: monoclonal anti-IL-11 (R&D Systems, Minneapolis, MN), polyclonal anti-IL-11Ralpha (Santa Cruz Biotechnology, Santa Cruz, CA), anti-glutathione S transferase (GST) (Amersham Pharmacia Biotech. Piscataway, NJ), anti-human Fc HRP-conjugated (Sigma-Aldrich, St. Louis, MO), and anti-STAT3 or anti-phospho-STAT3 (P-Tyr705) (Cell Signaling Technology, Beverly, MA). Recombinant proteins (rhIL-11, IL-11Ralpha, gp130 and LeptinR) were purchased from R&D Systems. Soluble CGRRAGGSC peptide was synthesized and cyclized at AnaSpec (San Jose, CA). Phage displaying the peptide CGRRAGGSC or its scrambled version CRGSGAGRC have been described [1], [2].
###end p 51
###begin title 52
Phage binding assay
###end title 52
###begin p 53
###xml 87 90 83 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 92 95 88 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Zurita1">[2]</xref>
###xml 252 256 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Smith1">[60]</xref>
###xml 501 502 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 708 711 690 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Arap1">[1]</xref>
###xml 195 200 <span type="species:ncbi:9606">human</span>
###xml 424 430 <span type="species:ncbi:9913">bovine</span>
CGRRAGGSC phage recovered in vivo served for in vitro binding to IL-11Ralpha and gp130 [1], [2]. IL-11Ralpha, gp130 or control leptin receptor (the extracellular domain fused to the Fc region of human IgG; R&D Systems) were coated on microtiter wells. [60]. Proteins were immobilized (2 microg/ml) on microtiter wells overnight at 4degreesC, washed twice with phosphate buffered saline (PBS), blocked PBS containing with 3% bovine serum albumin (BSA) for 2 h at room temperature, and incubated with 109 TU of targeted or negative control phage (insertless). After 1 h at room temperature, wells were washed twelve times with PBS, and bound phage were recovered by bacterial infection and plated as described [1].
###end p 53
###begin title 54
NMR spectroscopy
###end title 54
###begin p 55
###xml 211 212 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 291 295 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Piotto1">[61]</xref>
###xml 458 462 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Bax1">[62]</xref>
###xml 543 547 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003452-Sklenar1">[63]</xref>
###xml 565 566 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 836 837 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 956 966 932 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003452.s001">Figure S1B</xref>
NMR experiments were acquired on a 600 MHz spectrometer (Bruker Avance DRX). CGRRAGGSC (400 microM) chemical shift assignment was performed in 50 mM sodium phosphate buffer containing 5 mM sodium azide and 10% D2O. Two-dimensional spectra were collected with 1,024 transients. NOESY spectra [61] were acquired with 150 ms mixing time. Spectra were collected (4,096 F1 points, 512 F2 points). TOCSY spectra (spin-lock time = 80 ms) were acquired with MLEV-17 [62] (4,096 F1 points, 512 F2 points). Water suppression was achieved with WATERGATE [63]. One-dimensional 1H-NMR spectra of peptide in the presence of IL-11Ralpha (6 microM) were obtained. Chemical shift perturbations were followed by TOCSY and NOESY by comparison of the spectra of CGRRAGGSC (400 microM) free in solution or in the presence of IL-11Ralpha. Analysis of the 1D-1H-NMR spectra with increasing concentrations of CGRRAGGSC (up to 400 microM) revealed no significant resonance shifts (Figure S1B), data indicating that the peptide was monomeric. Sodium 2,2-dimethyl-2-silapentane-5-sufonate (70 microM) served as a standard for precise spectral overlapping.
###end p 55
###begin title 56
Protein expression and purification
###end title 56
###begin p 57
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 196 202 192 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">595 nm</sub>
###xml 49 61 <span type="species:ncbi:511693">E. coli BL21</span>
IL-11 alanine-scanning mutants were expressed in E. coli BL21 and purified from inclusion bodies. In brief, cells were cultured in 2xYT media supplemented with 200 microg/ml carbenicillin until OD595 nmapproximately0.6, at which point GST expression was induced with 1 mM IPTG. After 4 h of induction, bacteria were collected by centrifugation (5,000 g for 10 min) and lysed with BugBuster reagent (EMD Biosciences, CA) according to the manufacturer's recommendations. GST-IL-11 fusion proteins within the inclusion body fractions were collected by centrifugation at 28,000 g for 30 min and washed with 8 M urea in PBS. The purified inclusion bodies were solubilized in 6 M guanidine-HCl, 50 mM Tris-HCl pH 8, 100 mM NaCl, 10 mM EDTA, and 10 mM DTT at 0.5 to 1 mg/ml (solubilization buffer). Purified recombinant proteins were analyzed by staining with Coomassie Brilliant Blue, and Western blot with anti-IL-11 and anti-GST antibodies. To confirm the proper folding of the IL-11-GST mutants, Western blot with one polyclonal anti-IL-11 and two monoclonal anti-IL-11 antibodies were performed (data not shown).
###end p 57
###begin title 58
IL-11 site-directed mutagenesis
###end title 58
###begin p 59
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BamH</italic>
###xml 130 133 130 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
###xml 590 593 574 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pfu</italic>
###xml 823 874 807 858 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTGCGGCACGTGCAGTGGCTGGCCCGGGCAGGTGGCTCTTCCCTG-3&#8242;</named-content>
###xml 883 934 867 918 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCACGTGCAGTGGCTGCGCGCGGCAGGTGGCCTCTCCCTGAAG-3&#8242;</named-content>
###xml 943 994 927 978 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTGCAGTGGCTGCGCCGGGCAGCTGGCTCTTCCCTGAAGACCCTG-3&#8242;</named-content>
###xml 1003 1054 987 1038 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGTGGCTGCGCCGGGCAGGTGCCTCTTCCCTGAAGACCCTGGAG-3&#8242;</named-content>
###xml 1063 1114 1047 1098 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGGCTGCGCCGGGCAGGTGGCGCTTCCCTGAAGACCCTGGAGCCC-3&#8242;</named-content>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human IL-11 cDNA clone was obtained from Invitrogen (Clone ID 4476678). We designed specific PCR primers containing BamHI and NotI for PCR amplification and directional cloning of the IL-11 open reading frame in the pGEX4T-1 prokaryotic expression vector (Amersham). The GST-IL-11 clone was sequenced to confirm the fusion of both proteins. We used the GST-IL-11 plasmid as a template for the generation of the IL-11 mutants. PCR mutagenesis was performed in a reaction volume of 50 microl that included 1 microL plasmid DNA (20 ng/microl), 10 pmol primers, 200 microM dNTPs, and 2.5 U Pfu Ultra high fidelity DNA polymerase (Stratagene, La Jolla, CA). Sense and antisense primers were designed to substitute nucleotides and to introduce an alanine residue. The oligonucleotides used for IL-11 mutagenesis were: R112A, 5'-CTGCGGCACGTGCAGTGGCTGGCCCGGGCAGGTGGCTCTTCCCTG-3'; R113A, 5'-CGGCACGTGCAGTGGCTGCGCGCGGCAGGTGGCCTCTCCCTGAAG-3'; G115A, 5'-GTGCAGTGGCTGCGCCGGGCAGCTGGCTCTTCCCTGAAGACCCTG-3'; G116A, 5'-CAGTGGCTGCGCCGGGCAGGTGCCTCTTCCCTGAAGACCCTGGAG-3'; S117A, 5'-TGGCTGCGCCGGGCAGGTGGCGCTTCCCTGAAGACCCTGGAGCCC-3'. A preliminary denaturation step at 95degreesC for 3 min was followed by 20 cycles of PCR. These PCR cycles consisted of 30 s of denaturation at 95degreesC, 1 min of annealing at 65degreesC and 10 min of extension at 72degreesC. Finally the PCR product was treated with 1 microl DpnI endonuclease for 2 h at 37degreesC, and 2 microl DpnI-digested DNA was transformed into 50 microl DH5alpha competent bacteria. Colonies were picked for plasmid isolation (QIAGEN, Valencia, CA), and nucleotide sequence analysis was performed at the DNA Core Facility, M.D. Anderson Cancer Center (Houston, TX).
###end p 59
###begin title 60
ELISA assay
###end title 60
###begin p 61
###xml 467 472 <span type="species:ncbi:9606">human</span>
GST fusion proteins of wild-type IL-11, alanine scan mutants of amino acids 112 to 117 of IL-11, or GST alone were coated overnight onto 96-well plates at 5 microg/ml. Recombinant IL-11 was added at 2 microg/ml. Wells were subsequently rinsed with wash buffer (0.1% Tween in PBS), followed by incubation with a blocking buffer (3% BSA in PBS) for 1 h at room temperature (RT). IL-11Ralpha (1 microg/ml) was added and incubated for 2 h. Binding was detected with anti-human Fc HRP-conjugated antibody (1:5000). To confirm adequacy of coating, we performed parallel ELISAs with anti-GST antibody (1:1500, data not shown). Leptin receptor was used as Fc protein and binding specificity control.
###end p 61
###begin title 62
Alanine-scanning mutagenesis of phage-displayed peptides
###end title 62
###begin p 63
###xml 453 456 447 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sfi</italic>
###xml 722 743 716 737 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTGAGCCGGCTGCCC-3&#8242;</named-content>
###xml 748 769 742 763 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTCGGCCCCAGCGGC-3&#8242;</named-content>
###xml 888 891 882 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bgl</italic>
###xml 919 922 913 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sfi</italic>
###xml 1011 1018 1001 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 1130 1178 1120 1168 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCTTGTGCGCGGAGGGCGGGCGGTTCGTGTGGGGCCGCTG-3&#8242;</named-content>
###xml 1199 1247 1189 1237 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCCCCACACGAACCGCCCGCCCTCCGCGCACAAGCCCCGT-3&#8242;</named-content>
###xml 1268 1316 1258 1306 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCTTGTGGGGCGAGGGCGGGCGGTTCGTGTGGGGCCGCTG-3&#8242;</named-content>
###xml 1337 1385 1327 1375 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCCCCACACGAACCGCCCGCCCTCGCCCCACAAGCCCCGT-3&#8242;</named-content>
###xml 1406 1454 1396 1444 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCTTGTGGGCGGGCGGCGGGCGGTTCGTGTGGGGCCGCTG-3&#8242;</named-content>
###xml 1475 1523 1465 1513 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCCCCACACGAACCGCCCGCCGCCCGCCCACAAGCCCCGT-3&#8242;</named-content>
###xml 1544 1592 1534 1582 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCTTGTGGGCGGAGGGCGGCGGGTTCGTGTGGGGCCGCTG-3&#8242;</named-content>
###xml 1613 1661 1603 1651 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCCCCACACGAACCCGCCGCCCTCCGCCCACAAGCCCCGT-3&#8242;</named-content>
###xml 1682 1730 1672 1720 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCTTGTGGGCGGAGGGCGGGCGCGTCGTGTGGGGCCGCTG-3&#8242;</named-content>
###xml 1751 1799 1741 1789 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCCCCACACGACGCGCCCGCCCTCCGCCCACAAGCCCCGT-3&#8242;</named-content>
###xml 1820 1868 1810 1858 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCTTGTGGGCGGAGGGCGGGCGGTGCGTGTGGGGCCGCTG-3&#8242;</named-content>
###xml 1889 1937 1879 1927 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGCCCCACACGCACCGCCCGCCCTCCGCCCACAAGCCCCGT-3&#8242;</named-content>
###xml 1011 1018 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
DNA sequences encoding residue substitutions were introduced into the peptide CGRRAGGSC as indicated. Self-annealing synthetic oligonucleotides (Sigma-Genosys, Woodlands, TX) were combined and resuspended in annealing buffer (10 mM Tris-HCl pH 8.0, containing 100 mM NaCl and 1 mM EDTA) at 10 nM. Oligonucleotide mixtures were heated to 100degreesC for 5 min and cooled down to RT over a 30 min. Self-annealed oligonucleotides were directly cloned into SfiI-digested fUSE5 vector by using T4 DNA ligase (Roche Applied Science, Indianapolis, IN). Alternatively, 500 ng of the synthetic oligonucleotide templates encoding the displayed peptides were converted to double-stranded DNA by PCR amplification with the primer set 5'-GTGAGCCGGCTGCCC-3' and 5'-TTCGGCCCCAGCGGC-3', and Taq-DNA polymerase (Promega, Madison, WI). Double-stranded PCR products were treated with the restriction enzyme BglII and were cloned into the SfiI-digested fUSE5 vector. In all cases, plasmids were transformed into competent DH5alpha E. coli, and DNA was verified by sequencing. Oligonucleotides used for the mutational studies were: CARRAGGSC-forward, 5'-GGGCTTGTGCGCGGAGGGCGGGCGGTTCGTGTGGGGCCGCTG-3'; CARRAGGSC-reverse, 5'-CGGCCCCACACGAACCGCCCGCCCTCCGCGCACAAGCCCCGT-3'; CGARAGGSC-forward, 5'-GGGCTTGTGGGGCGAGGGCGGGCGGTTCGTGTGGGGCCGCTG-3'; CGARAGGSC-reverse, 5'-CGGCCCCACACGAACCGCCCGCCCTCGCCCCACAAGCCCCGT-3'; CGRAAGGSC-forward, 5'-GGGCTTGTGGGCGGGCGGCGGGCGGTTCGTGTGGGGCCGCTG-3'; CGRAAGGSC-reverse, 5'-CGGCCCCACACGAACCGCCCGCCGCCCGCCCACAAGCCCCGT-3'; CGRRAAGSC-forward, 5'-GGGCTTGTGGGCGGAGGGCGGCGGGTTCGTGTGGGGCCGCTG-3'; CGRRAAGSC-reverse, 5'-CGGCCCCACACGAACCCGCCGCCCTCCGCCCACAAGCCCCGT-3'; CGRRAGASC-forward, 5'-GGGCTTGTGGGCGGAGGGCGGGCGCGTCGTGTGGGGCCGCTG-3'; CGRRAGASC-reverse, 5'-CGGCCCCACACGACGCGCCCGCCCTCCGCCCACAAGCCCCGT-3'; CGRRAGGAC-forward, 5'-GGGCTTGTGGGCGGAGGGCGGGCGGTGCGTGTGGGGCCGCTG-3'; CGRRAGGAC-reverse, 5'-CGGCCCCACACGCACCGCCCGCCCTCCGCCCACAAGCCCCGT-3'.
###end p 63
###begin p 64
Phage binding with the alanine-scanning displaying phage were performed as described above. Insertless and IL-11-like phage served as a negative and positive control. All experiments were performed in duplicate and repeated at least four times with similar results.
###end p 64
###begin title 65
Cell culture and proliferation
###end title 65
###begin p 66
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fgf-4</italic>
###xml 673 678 <span type="species:ncbi:9606">human</span>
###xml 961 966 <span type="species:ncbi:9606">human</span>
Growth factor-dependent erythroleukemia cells (TF-1) were obtained from the American Type Culture Collection (ATCC; Manassas, VA) and were cultured in RPMI-1640 containing L-glutamine, sodium bicarbonate, glucose, HEPES, sodium pyruvate, 10% FBS, and 2 ng/ml recombinant GM-CSF (R&D Systems). EF43.fgf-4, which served as control cells unless otherwise specified, were maintained in DMEM containing high glucose and 10% FBS. Cell proliferation was measured by metabolic conversion of WST-1 to formazan (Roche). Cells were incubated in 96-well dishes (30,000 cells/well) with RPMI-1640 containing 1% FBS plus 3, 10, 30, 100, 300, or 1,000 microM CGRRAGGSC and/or recombinant human IL-11 (0.5 ng/ml) at 37degreesC for 72 h. GM-CSF (0.01 ng/ml) served as a positive control for proliferation, and an unrelated peptide (CGSPGWVRC) was used as a negative control. Inhibition of CGRRAGGSC-induced cell proliferation was assessed in the presence of 100 ng/ml of either human sIL-11Ralpha or soluble leptin receptor (negative control).
###end p 66
###begin title 67
STAT3 activation assay
###end title 67
###begin p 68
###xml 735 738 726 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">705</sup>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 790 796 <span type="species:ncbi:9986">rabbit</span>
TF-1 cells (750,000 cells/well, 24-well dishes) were incubated 18-24 hr in serum-free RPMI-1640. Subsequently, CGRRAGGSC or negative control peptide (100 microM each), either alone or in combination with human IL-11 (10 ng/ml), was added for 15 min. For experiments measuring concentration-dependence, the concentrations were 3, 10, 30 and 100 microM (peptides) or 3, 10, 30 and 100 ng/ml (IL-11). Cells were centrifuged, extracts were solubilized with Laemmli sample buffer containg ss-mercatptoethanol, lysates were resolved on 4-20% gradient SDS-PAGE gels and bands were transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes were blocked and subsequently incubated with anti-STAT3 or anti-phospho-STAT3 (P-Tyr705) antibodies (1:1,000) followed by HRP-coupled anti-rabbit antibody (1:2000; Bio-Rad). Detection was by ECL (Amersham). Commercial HeLa cell extracts treated or not treated with interferon-alpha (Cell Signaling) served as controls.
###end p 68
###begin title 69
Supporting Information
###end title 69
###begin p 70
The IL-11 mimic peptide CGRRAGGSC is multiconformational and monomeric (A) Amide region of the 1D-1H-NMR of CGRRAGGSC peptide (400 microM) at 25degreesC and at 5degreesC. (B) The amide regions of 1D-1H-NMR spectra under increasing concentrations of the IL-11-like peptide CGRRAGGSC at 25degreesC are shown. The presence of broad lines indicates peptide conformational exchange. No peptide oligomerization induced by increasing concentrations of CGRRAGGSC (up to 400 microM) was observed under the experimental conditions used.
###end p 70
###begin p 71
(0.53 MB TIF)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin p 73
Chemical shift for the IL-11-like peptide
###end p 73
###begin p 74
(0.05 MB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
Chemical shift for new resonances in CGRRAGGSC
###end p 76
###begin p 77
(0.03 MB DOC)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
We thank Dr. E. Helene Sage and Michael G. Ozawa for insightful discussions.
###end p 79
###begin title 80
References
###end title 80
###begin article-title 81
###xml 25 30 <span type="species:ncbi:9606">human</span>
Steps toward mapping the human vasculature by phage display.
###end article-title 81
###begin article-title 82
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer.
###end article-title 82
###begin article-title 83
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
###end article-title 83
###begin article-title 84
Anti-cancer activity of targeted pro-apoptotic peptides.
###end article-title 84
###begin article-title 85
Tumor targeting with a selective gelatinase inhibitor.
###end article-title 85
###begin article-title 86
Biopanning and rapid analysis of selective interactive ligands.
###end article-title 86
###begin article-title 87
Aminopeptidase A is a functional target in angiogenic blood vessels.
###end article-title 87
###begin article-title 88
Reversal of obesity by targeted ablation of adipose tissue.
###end article-title 88
###begin article-title 89
Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.
###end article-title 89
###begin article-title 90
A hybrid vector for ligand-directed tumor targeting and molecular imaging.
###end article-title 90
###begin article-title 91
A multigenic program mediating breast cancer metastasis to bone.
###end article-title 91
###begin article-title 92
Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma.
###end article-title 92
###begin article-title 93
Interleukin-11: review of molecular, cell biology, and clinical use.
###end article-title 93
###begin article-title 94
Receptor recognition by gp130 cytokines.
###end article-title 94
###begin article-title 95
Principles of interleukin (IL)-6-type cytokine signalling and its regulation.
###end article-title 95
###begin article-title 96
###xml 40 45 <span type="species:ncbi:9606">human</span>
Definition of receptor binding sites on human interleukin-11 by molecular modeling-guided mutagenesis.
###end article-title 96
###begin article-title 97
###xml 36 41 <span type="species:ncbi:9606">human</span>
Structure-function relationships in human interleukin-11. Identification of regions involved in activity by chemical modification and site-directed mutagenesis.
###end article-title 97
###begin article-title 98
###xml 32 37 <span type="species:ncbi:9606">human</span>
Alanine-scanning mutagenesis of human interleukin-11: identification of regions important for biological activity.
###end article-title 98
###begin article-title 99
###xml 29 34 <span type="species:ncbi:9606">human</span>
Characterization of a potent human interleukin-11 agonist.
###end article-title 99
###begin article-title 100
###xml 59 65 <span type="species:ncbi:10090">murine</span>
Identification of three distinct receptor binding sites of murine interleukin-11.
###end article-title 100
###begin article-title 101
Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions.
###end article-title 101
###begin article-title 102
Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
###end article-title 102
###begin article-title 103
###xml 36 41 <span type="species:ncbi:9606">human</span>
Identification of the domain in the human interleukin-11 receptor that mediates ligand binding.
###end article-title 103
###begin article-title 104
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.
###end article-title 104
###begin article-title 105
The cytokine receptor gp130: faithfully promiscuous.
###end article-title 105
###begin article-title 106
Bow to your partner for signaling.
###end article-title 106
###begin article-title 107
Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane.
###end article-title 107
###begin article-title 108
IL-6 type cytokine receptor complexes: hexamer, tetramer or both?
###end article-title 108
###begin article-title 109
Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors.
###end article-title 109
###begin article-title 110
Implications of protein conformational diversity for binding and development of new biological active compounds.
###end article-title 110
###begin article-title 111
Solution structures of the YAP65 WW domain and the variant L30 K in complex with the peptides GTPPPPYTVG, N-(n-octyl)-GPPPY and PLPPY and the application of peptide libraries reveal a minimal binding epitope.
###end article-title 111
###begin article-title 112
Structural biology of membrane-acting peptides: conformational plasticity of anticoccidial peptide PW2 probed by solution NMR.
###end article-title 112
###begin article-title 113
Dynamic personalities of proteins.
###end article-title 113
###begin article-title 114
Intrinsic motions along an enzymatic reaction trajectory.
###end article-title 114
###begin article-title 115
Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor.
###end article-title 115
###begin article-title 116
###xml 77 89 <span type="species:ncbi:9606">participants</span>
Revisiting ethical guidelines for research with terminal wean and brain-dead participants.
###end article-title 116
###begin article-title 117
Ethics guidelines for research with the recently dead.
###end article-title 117
###begin article-title 118
1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling.
###end article-title 118
###begin article-title 119
###xml 29 34 <span type="species:ncbi:9606">human</span>
Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing.
###end article-title 119
###begin article-title 120
Localization of functional receptor epitopes on the structure of ciliary neurotrophic factor indicates a conserved, function-related epitope topography among helical cytokines.
###end article-title 120
###begin article-title 121
Interleukin-6: structure-function relationships.
###end article-title 121
###begin article-title 122
###xml 50 55 <span type="species:ncbi:9606">human</span>
Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists.
###end article-title 122
###begin article-title 123
###xml 52 57 <span type="species:ncbi:9606">human</span>
Definition of a composite binding site for gp130 in human interleukin-6.
###end article-title 123
###begin article-title 124
Structure of an extracellular gp130 cytokine receptor signaling complex.
###end article-title 124
###begin article-title 125
Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6.
###end article-title 125
###begin article-title 126
###xml 44 49 <span type="species:ncbi:9606">human</span>
Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6.
###end article-title 126
###begin article-title 127
###xml 38 43 <span type="species:ncbi:9606">human</span>
Reconstitution of two isoforms of the human interleukin-11 receptor and comparison of their functional properties.
###end article-title 127
###begin article-title 128
Small peptides as potent mimetics of the protein hormone erythropoietin.
###end article-title 128
###begin article-title 129
Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A.
###end article-title 129
###begin article-title 130
Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.
###end article-title 130
###begin article-title 131
An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation.
###end article-title 131
###begin article-title 132
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.
###end article-title 132
###begin article-title 133
Peptides identify the critical hotspots involved in the biological activation of the insulin receptor.
###end article-title 133
###begin article-title 134
###xml 46 51 <span type="species:ncbi:9606">human</span>
Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.
###end article-title 134
###begin article-title 135
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human interleukin-6 (IL-6) receptor exists as a preformed dimer in the plasma membrane.
###end article-title 135
###begin article-title 136
Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling.
###end article-title 136
###begin article-title 137
Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies.
###end article-title 137
###begin article-title 138
Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor.
###end article-title 138
###begin article-title 139
###xml 48 65 <span type="species:ncbi:12420">filamentous phage</span>
Libraries of peptides and proteins displayed on filamentous phage.
###end article-title 139
###begin article-title 140
Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions.
###end article-title 140
###begin article-title 141
Mlev-17-Based Two-Dimensional Homonuclear Magnetization Transfer Spectroscopy.
###end article-title 141
###begin article-title 142
Gradient-tailored water suppression for H-1-N-15 Hsqc experiments optimized to retain full sensitivity.
###end article-title 142
###begin p 143
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 143
###begin p 144
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the Specialized Program in Research Excellence (SPORE) of the National Cancer Institute (to WA and RP), from the U.S. Department of Defense (to MGK, WA, and RP), and by awards from the Prostate Cancer Foundation, the Marcus Foundation and the Gillson-Longenbaugh Foundation (to WA and RP). MCV received a postdoctoral fellowship from the Susan G. Komen Breast Cancer Foundation. AJZ received a postdoctoral fellowship from the Instituto de Salud Carlos III (Spain); RR is a Scholar from the Odyssey Program of The University of Texas M. D. Anderson Cancer Center. CDA received a predoctoral fellowship from the National Research Council (Brazil). FCLA and APV received support from the Rio de Janeiro State Research Support Foundation and the National Research Council (Brazil). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 144

